Back

Pharvaris presents oral deucrictibant data at 2026 Bradykinin Symposium

Verifying
  • Pharvaris summarized deucrictibant presentations at the Bradykinin Symposium 2026.
  • RAPIDe-3 median complete attack resolution took 11.61 hours in North America and 12.04 hours elsewhere.
  • CHAPTER-1 extension treatment lasted 22.2 months on average, with maximum exposure reaching 33.8 months.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.